-
Bayer completed its acquisition of Monsanto with sales of EUR 9,481 million in the second quarter
Time of Update: 2021-02-27
Recently, Bayer reported second quarter 2018 results, during which the Group's sales increased by 8.5% (adjusted for exchange rate and portfolio) to EUR 9,481 million.
's health consumer goods business continued to decline sales of self-care products (health consumer goods) fell 1.4 per cent (adjusted for exchange rates and portfolio) to EUR 1,413 million.
-
Fosun Pharma's net profit decreased by 13.44% in the first three quarters
Time of Update: 2021-02-27
Fosun Pharma explained the decline in net profit in its third-quarter report, saying it was mainly affected by higher investment in innovative research and development and business layout, losses at some participating companies and higher interest expense.
-
Ali pharmaceutical ecosystem gradually become a pharmacy's way of survival where to find
Time of Update: 2021-02-27
As the name implies, that is, leading enterprises to integrate the ability, advantages, resources and so on of all parties inside and outside the industry, in a certain range to form a mutually dependent, interdependent, symbiotic ecosystem, a virtuous circle, in order to achieve strategic objectives more quickly.
-
Shangrong Healthcare's failed expansion lost its share price by 83.1 billion yuan, shrinking by 1.8 billion yuan
Time of Update: 2021-02-27
, according to the announcement, on April 4 this year, Shangrong Medical issued a plan for the 2018 public offering of convertible corporate bonds, saying that the company intends to issue convertible bonds, raising a total of not more than 900 million yuan.
-
East A gum quarterly report: net profit of 363 million, up 5.13% YoY
Time of Update: 2021-02-27
At the Xipu Conference held on August 13 this year, the 2018 "China Pharmaceutical Brand List Value List" was announced, with Dong'a gum taking the top spot and achieving its fourth consecutive crown since 2015, further consolidating the position of high-end nourishing health brands.
-
North China Pharmaceuticals reported a 254.32% year-on-year increase in net profit for the third quarter
Time of Update: 2021-02-27
On October 17, North China Pharmaceuticals released its third-quarter report, reporting that the company's operating income for the January-September period was 7 billion yuan, and the net profit attr
-
650 million China Resources Pharmaceuticals commercial shares in the Inte Group is close to Zhejiang
Time of Update: 2021-02-27
65 million, China Resources Pharmaceuticals Commercial, equity in TheIt Group On September 25, Zhejiang Inte Group announced that it intends to raise no more than 650 million yuan through a non-public offering of shares, and that the number of shares issued in private will not exceed 20% of the total share capital of the previously issued company.
-
Jiangzhong's acquisition of Sanghai Pharmaceuticals and Jisheng Pharmaceuticals' commitment to China Resources is only one step
Time of Update: 2021-02-27
Jiang Traditional Chinese Medicine will soon be included in the "China Resources Map follow-up to June 2 Jiangsao Pharmaceuticals issued "on the company's actual controller to change the prompt announcement" shows that China Resources Pharmaceutical Holdings intends to increase capital and purchase part of Jiangxi Jiang zhong pharmaceutical (Group) Co., Ltd. shares in the combination of the acquisition of Jiang zhong group not less than 51% of the shares.
-
China Resources Medicine "eats" stomach-churning tablets
Time of Update: 2021-02-27
"Daily Economic News" reporter learned that after the completion of the capital increase, China Resources Pharmaceutical Holdings will hold a 51% stake in Jiang zhong group, thereby indirectly controlling jiang chinese medicine has issued shares of 43.03 percent.
-
Lepu Medical: The results of the mid-to-long-term business layout are bright and fruitful
Time of Update: 2021-02-27
Drug sector maintained high growth, consistent evaluation of the bend oversized the pharmaceutical sector is currently the fastest growing sector, the first half of the operating income of 1.428 billion yuan, up 70.63 percent year-on-year, net profit of 435 million yuan, up 70.71 percent year-on-year, with the 2017 annual and semi-annual reports of 71 percent.
-
Huaren Pharmaceuticals' proposed acquisition of Korean medicine and cosmetics marriage will have a "spark"?
Time of Update: 2021-02-27
On the evening of October 17th, Huaren Pharmaceuticals, which had earlier announced that it would acquire a well-known cosmetics company in China, finally lifted the mystery of the target, which was acquired by Han post cosmetics Co., Ltd.
-
Ali Health has teamed up with a number of chain pharmacies to test the new retail of water medicine
Time of Update: 2021-02-27
August 20, Ali Health and Rookie Network announced that in Hangzhou, the first 24-hour online purchase of medicine 30 minutes on-line delivery service, no hiccups at night, within 1 hour of delivery.
-
Huada Gene's 100 billion-dollar market capitalization pharmaceutical company "collapse" is now only 29.6 billion
Time of Update: 2021-02-27
July 14th, Huada Gene issued a clarification announcement in the media, responding to questions about non-invasional prenatal genetic testing technology and whether there was exaggerated propaganda.
-
Comey Pharmaceuticals responded by questioning that major shareholders would reduce the proportion of pledges
Time of Update: 2021-02-27
For the large balance of book money funds, Kangmei Pharmaceuticals explained that according to the company's strategic planning, new project investment, industrial mergers and acquisitions and trade in Chinese herbal medicine, such as the demand for monetary funds and financing scale is very large.
-
Net profit down 60% deduction non-net profit increased by nearly 40% Temple of Heaven biological transformation pain period?
Time of Update: 2021-02-27
According to the announcement disclosed by Tiantan Bio, in the first three quarters of 2017, Tiantan Bio transferred its 100% stake in Beijing Beisheng Research Biological Products Co., Ltd. and 51% stake in Changchun Jian Biological Products Co., Ltd., achieving an investment income (after tax) of 758 million yuan, mainly affected by this, the company's operating profit, total profit, net profit attributable to shareholders of listed companies, basic earnings per share decreased significantly in the first three quarters of 2018.
-
Affected by Hurricane Maria, Haizheng Pharmaceuticals is back out of stock
Time of Update: 2021-02-27
in late May 2018, Hanyu Pharmaceuticals received notification from Pfizer that its Puerto Rico plant had been severely damaged by Hurricane Maria late last year, resulting in a degree of supply constraints for Refinan finished products in the Chinese market.
-
Chuanmei Medical A-share IPO will challenge the GEM IPO record
Time of Update: 2021-02-27
on the eve of the 2015 Chinese stock market disaster, Myer International launched the privatization of American Depositarius shares listed on the New York Stock Exchange and de-listed them from the United States in March 2016 at a cost of approximately $2.46 billion, according to the filing.
-
Connbey's first three-quarter results exceeded last year's full-year stake in the company increased to 4.38 percent
Time of Update: 2021-02-27
For The first three quarters of this year to achieve a substantial increase in revenue and stable growth in net profit, the company's chairman Hu Jiqiang said, mainly due to the promotion and implementation of large-brand large-variety projects, at the same time, launched in February this year, science and technology innovation-driven development projects, both to enhance the competitiveness of the company's existing products, but also for the company's future business development laid the foundation.
-
Step Pharmaceutical semi-annual report released the pace of transformation and innovation accelerated
Time of Update: 2021-02-27
Recently, Step Pharmaceuticals issued an announcement. According to the announcement, the company achieved operating income of RMB5,748 million, down 0.06% from a year earlier, and net profit attribut
-
Medical industry "veteran" Yangzijiang Pharmaceuticals New Bureau
Time of Update: 2021-02-27
According to Yao Zhongqing, executive vice president of the Institute of Traditional Chinese Medicine of Yangzijiang Pharmaceutical Group, the current cost of research and development of single varieties of innovative Chinese medicine drugs needs to be invested at least 50 million yuan to 100 million yuan, and the effective ingredient innovation drugs need at least 200 million yuan.
